Brand name: Capecitabine (Apotex)
Capecitabine (Apotex) is a medicine containing the active ingredient(s) capecitabine. On this page you will find out more about Capecitabine (Apotex), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: capecitabine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Capecitabine (Apotex) 500 mg film-coated tablet, 120
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Colon Cancer,Capecitabine is indicated for the adjuvant treatment of patients with Dukes' stage C and high-risk stage B, colon cancer, either as monotherapy or in combination with oxaliplatin.,Colorectal Cancer,Capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.,Oesophagogastric Cancer,Capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.,Breast Cancer,Capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated.,Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance |
Peach, oval, biconvex, film-coated tablet. Engraved APO on one side, C500 on the other side.
Images are the copyright of the Pharmacy Guild of Australia |
| Dosage Form | Tablet, film coated |
| Route of administration | Oral |
| Medicine schedule |
120: Prescription Only Medicine, or Prescription Animal Remedy
|
There is one type of pack available.
Pack type 1
| Type | Blister Pack |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | No information available |
| Life time | 36 Months |
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 October 2017
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
